Phosphorus, a genomic health company offering diagnostic genetic tests and clinical software, have released advanced tests for hereditary cancers. The tests include a high-risk panel for common cancers, a comprehensive panel spanning multiple cancer types, and fully-customizable panels by specialty area covering up to 114 total genes associated with inherited cancers.
Genetic testing is a powerful tool for identification of individuals who are at increased risk for developing cancer. It is important for assessing cancer risk, improving cancer survival rates, and planning management of high-risk patients, including steps such as increased surveillance and targeted medication.
Phosphorus's expert-curated panels, powerful data analytics, and rigorous variant interpretations have been designed and developed to ensure the most accurate results for patients. The tests are powered by next-generation sequencing technology, including comprehensive detection of copy number variants.
The newly-launched genetic tests are organized into three panels-Common/High-Risk Panel for examining the most actionable and widely-recognized genes across cancer types to provide clear prophylactic and treatment options, Pan Cancer Panel for examining a broad range of genes across cancer types to give broader insight into cancer risk, and Disease-specific panels including breast, colorectal, brain/nervous system, leukemia, pancreatic, ovarian/uterine, renal, thyroid, melanoma, prostate, and pediatric cancers.
